Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2012

Study Completion Date

December 31, 2012

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Risperidone

Dosage of 0.5 mg to 4.0 mg per day as tolerated

BEHAVIORAL

Exposure/ritual prevention therapy (EX/RP)

EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.

DRUG

Placebo

Placebo capsules will be identical in appearance to those of risperidone.

Trial Locations (2)

10032

New York State Psychiatric Institute, New York

19104

University of Pennsylvania Center for the Treatment and Study of Anxiety, Philadelphia

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT00389493 - Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder | Biotech Hunter | Biotech Hunter